0001567619-22-006130.txt : 20220302 0001567619-22-006130.hdr.sgml : 20220302 20220302204012 ACCESSION NUMBER: 0001567619-22-006130 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220301 FILED AS OF DATE: 20220302 DATE AS OF CHANGE: 20220302 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Zhen Marianne CENTRAL INDEX KEY: 0001750085 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30319 FILM NUMBER: 22706346 MAIL ADDRESS: STREET 1: C/O INNOVIVA, INC. STREET 2: 2000 SIERRA POINT PARKWAY, SUITE 500 CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Innoviva, Inc. CENTRAL INDEX KEY: 0001080014 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943265960 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1350 OLD BAYSHORE HIGHWAY STREET 2: SUITE 400 CITY: BURLINGAME STATE: CA ZIP: 94010 BUSINESS PHONE: 6502389600 MAIL ADDRESS: STREET 1: 1350 OLD BAYSHORE HIGHWAY STREET 2: SUITE 400 CITY: BURLINGAME STATE: CA ZIP: 94010 FORMER COMPANY: FORMER CONFORMED NAME: THERAVANCE INC DATE OF NAME CHANGE: 20020207 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED MEDICINE INC DATE OF NAME CHANGE: 20000302 4 1 doc1.xml FORM 4 X0306 4 2022-03-01 0 0001080014 Innoviva, Inc. INVA 0001750085 Zhen Marianne 1350 OLD BAYSHORE HIGHWAY, SUITE 400 BURLINGAME CA 94040 0 1 0 0 Chief Accounting Officer Common Stock 2022-03-01 4 A 0 6691 0 A 38872 D Non-statutory Stock Option 18.68 2022-03-01 4 A 0 15000 0 A 2023-02-20 2032-02-28 Common Stock 15000 20000 D The Reporting Person was granted a time-based restricted stock award ("RSA"). Twenty-five percent of the shares subject to the RSA shall vest on February 20, 2023, 6.25% on May 20, 2023, and an additional 6.25% on the final day of each 3-month period thereafter, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The grant was approved by the Compensation Committee of the Board of Directors of the Company. The Reporting Person was granted options. Twenty-five percent of the options shall vest on February 20, 2023, 6.25% on May 20, 2023, and an additional 6.25% on the final day of each 3-month period thereafter, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The grant was approved by the Compensation Committee of the Board of Directors of the Company. /s/ Marianne Zhen 2022-03-02